XML 41 R14.htm IDEA: XBRL DOCUMENT
v3.24.0.1

STOCK-BASED COMPENSATION | 12 Months Ended
--- | ---
Dec. 31, 2023
STOCK-BASED COMPENSATION |
STOCK-BASED COMPENSATION | 8. STOCK-BASED COMPENSATION In November 2015, our stockholders approved the 2015 Omnibus Long-Term Incentive Plan (“2015 LTIP”). Under the 2015 LTIP, 2,500,000 shares of common stock have been authorized for future grants to officers, directors, key employees and other persons. The 2015 LTIP provides for the grant of stock options, unrestricted stock, restricted stock, dividend equivalent rights, SSARs and cash awards. Any of these awards may, but need not, be made as performance incentives. Stock options granted under the 2015 LTIP may be non-qualified stock options or incentive stock options. We recognized stock-based compensation expense as follows (amounts in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Years Ended | ​ | Six Months Ended | ​ | Fiscal Year Ended
​ | ​ | December 31, | ​ | December 31, | ​ | December 31, | ​ | June 30,
​ |  | 2023 |  | 2022 |  | 2021 |  | 2021
Restricted stock | ​ | $ | 6,191 | ​ | $ | 4,515 | ​ | $ | 2,006 | ​ | $ | 2,668
Performance stock | ​ | ​ | 2,953 | ​ | ​ | 2,685 | ​ | ​ | 405 | ​ | ​ | 1,317
Stock appreciation rights | ​ | ​ | 533 | ​ | ​ | 1,179 | ​ | ​ | 779 | ​ | ​ | 1,677
Stock options | ​ | ​ | 19 | ​ | ​ | 32 | ​ | ​ | 28 | ​ | ​ | 68
Total stock-based compensation expense | ​ | $ | 9,696 | ​ | $ | 8,411 | ​ | $ | 3,218 | ​ | $ | 5,730
​ Stock-based compensation expense is included within General and administrative expense on the consolidated statements of operations and comprehensive income. Stock Options and Stock Appreciation Rights Stock option and SSARs awards are granted with an exercise price equal to the closing market price of our stock at the date of grant. Stock option and SSARs awards granted to officers, key employees and other persons vest based on one to three years of continuous service. Stock option and SSARs awards have 10-year contractual terms. There were no stock options or SSARs awards granted during the years ended December 31, 2023 and 2022, or the six months ended December 31, 2021. To determine stock-based compensation expense for stock options and SSARs, the fair value of each stock option and SSAR is estimated on the date of grant using the Black-Scholes-Merton (“Black-Scholes”) option pricing model for all periods presented. The Black-Scholes model requires key assumptions to determine fair value. Those key assumptions for the fiscal year June 30, 2021 grant is noted in the following tables: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Stock Options | ​
​ | ​ | Years Ended | ​ | Six Months Ended | ​ | Fiscal Year Ended | ​
​ | ​ | December 31, | ​ | December 31, | ​ | December 31, | ​ | June 30, | ​
​ | ​ | 2023 | ​ | 2022 | ​ | 2021 |  | 2021 |
Weighted-average expected volatility |  | — | % | — | % | — | % | 39.4 | %
Weighted-average expected life in years |  | — |  | — |  | — |  | 4.4 |
Weighted-average dividend yield |  | — | % | — | % | — | % | 0.9 | %
Weighted-average risk-free interest rate |  | — | % | — | % | — | % | 0.2 | %
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | SSARs |
​ | ​ | Years Ended | ​ | Six Months Ended | ​ | Fiscal Year Ended | ​
​ | ​ | December 31, | ​ | December 31, | ​ | December 31, | ​ | June 30, | ​
​ | ​ | 2023 | ​ | 2022 | ​ | 2021 | ​ | 2021 |
Weighted-average expected volatility | ​ | — | % | — | % | — | % | 39.2 | %
Weighted-average expected life in years | ​ | — |  | — |  | — |  | 4.2 | ​
Weighted-average dividend yield | ​ | — | % | — | % | — | % | 0.9 | %
Weighted-average risk-free interest rate | ​ | — | % | — | % | — | % | 0.2 | %
​ Our expected volatility is based on the historical volatility of our stock over the expected option term. Our expected option term is determined by historical exercise patterns along with other known employee or company information at the time of grant. The risk-free interest rate is based on the zero-coupon U.S. Treasury bond at the time of grant with a term approximate to the expected option term. Stock Options A summary of stock option activity for the year ended December 31, 2023, is presented below. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | ​ | ​ |  | Weighted- |  | ​ | ​
​ | ​ | ​ | ​ | Weighted- | ​ | Average | ​ | ​ | ​
​ | ​ | ​ | ​ | Average | ​ | Remaining | ​ | Aggregate
​ | ​ | Number of | ​ | Exercise | ​ | Contractual | ​ | Intrinsic Value
​ | ​ | Shares | ​ | Price | ​ | Life (Years) | ​ | (in thousands)
Outstanding at January 1, 2023 |  | 17,878 | ​ | $ | 81.17 |  |  |  | ​ |
Exercised |  | (6,534) | ​ | $ | 71.39 |  |  |  | ​ |
Forfeited |  | — | ​ | $ | — |  |  |  | ​ |
Granted |  | — | ​ | $ | — |  |  |  | ​ |
Outstanding at December 31, 2023 |  | 11,344 | ​ | $ | 86.80 |  | 3.4 | ​ | $ | 431
Exercisable at December 31, 2023 |  | 11,344 | ​ | $ | 86.80 |  | 3.4 | ​ | $ | 431
​ There were no stock options granted during the years ended December 31, 2023 and 2022 or the six months ended December 31, 2021. The weighted-average grant date fair value of options granted during the fiscal year ended June 30, 2021 was $41.92. The total intrinsic value of options exercised during the years ended December 31, 2023 and 2022 was $0.5 million and $0.2 million, respectively. There were no options exercised during the six months ended December 31, 2021 or fiscal year ended June 30, 2021. As of December 31, 2023, there was no unrecognized stock-based compensation expense related to unvested stock options. SSARs A summary of SSARs activity for the year ended December 31, 2023, is presented below: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | ​ | ​ |  | Weighted- |  | ​ | ​
​ | ​ | ​ | ​ | Weighted- | ​ | Average | ​ | ​ | ​
​ | ​ | ​ | ​ | Average | ​ | Remaining | ​ | Aggregate
​ | ​ | Number of | ​ | Exercise | ​ | Contractual | ​ | Intrinsic Value
​ | ​ | Shares | ​ | Price | ​ | Life (Years) | ​ | (in thousands)
Outstanding at January 1, 2023 |  | 174,906 | ​ | $ | 111.65 |  |  |  | ​ |
Exercised |  | (17,627) | ​ | $ | 99.34 |  |  |  | ​ |
Forfeited |  | — | ​ | $ | — |  |  |  | ​ |
Granted |  | — | ​ | $ | — |  |  |  | ​ |
Outstanding at December 31, 2023 |  | 157,279 | ​ | $ | 113.03 |  | 5.2 | ​ | $ | 2,526
Exercisable at December 31, 2023 |  | 157,279 | ​ | $ | 113.03 |  | 5.2 | ​ | $ | 2,526
​ There were no SSARs granted during the years ended December 31, 2023 and 2022 or the six months ended December 31, 2021. The weighted-average grant date fair value of SSARs granted during the fiscal year ended June 30, 2021 was $40.92. The total intrinsic value of SSARs exercised during the years ended December 31, 2023 and 2022, and fiscal year ended June 30, 2021 was $0.7 million, $0.2 million and $0.1 million, respectively. There were no SSARs exercised during the six months ended December 31, 2021. As of December 31, 2023, there was no unrecognized stock-based compensation expense related to unvested SSARs. ​ Other Stock-based Compensation Performance Shares During the years ended December 31, 2023 and 2022 and the six months ended December 31, 2021, officers and certain employees were granted shares of restricted common stock that may vest based on our total shareholder return (“TSR”) compared to the TSRs of certain defined members of the Van Eck Vectors Gold Miners ETF (“GDX”) (“Granted TSRs”). The Granted TSRs may vest by linear interpolation in a range between zero shares if neither threshold TSR metric is met; to 100% of the Granted TSRs awarded if the target TSR metric is met; to 200% of Granted TSRs awarded if the maximum TSR metric is met. The Granted TSRs will expire in three years from the date of grant if the TSR market condition is met and a three-year service condition is met. During the fiscal year ended June 30, 2021, officers and certain employees were granted shares of restricted common stock that can only be earned upon the achievement of certain pre-defined performance measures. Specifically, for performance shares granted during the fiscal year ended June 30, 2021, one-half of the shares awarded may vest upon our achievement of annual growth in Net Gold Equivalent Ounces (“Net GEOs”) (“GEO Shares”). The second half of performance shares granted during the fiscal year ended June 30, 2021 may vest based on our TSR compared to the TSRs of all members of the GDX (“Prior TSR Shares”). GEO Shares and Prior TSR Shares may vest by linear interpolation in a range between zero shares if neither threshold Net GEO and TSR metric is met; to 100% of GEO Shares and Prior TSR Shares awarded if both target Net GEO and TSR metrics are met; to 200% of the Net GEO and Prior TSR Shares awarded if both the maximum Net GEO and TSR metrics are met. The GEO Shares will expire in five years from the date of grant if the performance measure is not met, while the Prior TSR Shares will expire in three years from the date of grant if the TSR market condition and three-year service condition are not met. We measured the fair value of the GEO Shares based upon the market price of our common stock as of the date of grant. The measurement date for the GEO Shares will be determined at such time that the performance goals are attained or that it is probable they will be attained. At such time that it is probable that a performance condition will be achieved, compensation expense will be measured by the number of shares that will ultimately be earned based on the grant date market price of our common stock. For shares that were previously estimated to be probable of vesting and are no longer deemed to be probable of vesting, compensation expense is reversed during the period in which it is determined they are no longer probable of vesting. Interim recognition of compensation expense will be made at such time as management can reasonably estimate the number of shares that will be earned. GEO Shares granted in August 2020 and 2019 remain outstanding as of December 31, 2023 and the Company will continue to measure these awards for vesting until each awards expiration or performance attainment, whichever date is first. We measured the grant date fair value of the Granted TSRs and Prior TSR Shares using a Monte Carlo valuation model. The fair value of our TSR awards is multiplied by the target number (100%) of TSR awards granted to determine total stock-based compensation expense. Total stock-based compensation expense of the TSR awards is amortized on a straight-line basis over the requisite service period, or three years. Stock-based compensation expense for the TSR awards is recognized provided the requisite service period is rendered, regardless of when, if ever, the TSR market condition is satisfied. We will reverse previously recognized stock-based compensation expense attributable to the TSR awards only if the requisite service period is not met. A summary of the status of our unvested Performance Shares at maximum (200%) attainment for the year ended December 31, 2023, is presented below: ​
​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Weighted-
​ | ​ | ​ | ​ | Average
​ | ​ | Number of | ​ | Grant Date
​ | ​ | Shares | ​ | Fair Value
Outstanding at January 1, 2023 |  | 166,441 | ​ | $ | 122.05
Granted |  | 82,740 | ​ | $ | 139.50
Exercised |  | (5,847) | ​ | $ | 82.30
Non-attainment |  | (27,143) | ​ | $ | 79.84
Forfeited |  | — | ​ | $ | —
Outstanding at December 31, 2023 |  | 216,191 | ​ | $ | 135.11
​ As of December 31, 2023, total unrecognized stock-based compensation expense related to Performance Shares was approximately $5.7 million, which is expected to be recognized over the average remaining vesting period of 1.7 years. Restricted Stock Officers, non-executive directors and certain employees may be granted shares of restricted stock that vest on continued service alone (“Restricted Stock”). During the year ended December 31, 2023, officers and certain employees were granted 49,480 shares of Restricted Stock. Restricted Stock granted to officers and certain employees during the years ended December 31, 2023 and December 31, 2022 and the six months ended December 31, 2021, vest ratably over three years from the date of grant, while Restricted Stock granted to officers and certain employees during the fiscal year ended June 30, 2021 vest over three years beginning after a two-year holding period from the date of grant with one-third of the shares vesting in years three, four and five, respectively. Also, our non-executive directors were granted 7,230 shares of Restricted Stock during the year ended December 31, 2023. The non-executive directors’ shares of Restricted Stock vest 50% immediately and 50% one year after the date of grant. We measure the fair value of the Restricted Stock based upon the market price of our common stock as of the date of grant. Restricted Stock is amortized over the applicable vesting period using the straight-line method. Unvested shares of Restricted Stock are subject to forfeiture upon termination of employment or service. A summary of the status of our unvested Restricted Stock for the year ended December 31, 2023, is presented below: ​
​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Weighted-
​ | ​ | ​ | ​ | Average
​ | ​ | Number of | ​ | Grant Date
​ | ​ | Shares | ​ | Fair Value
Outstanding at January 1, 2023 |  | 120,542 | ​ | $ | 116.76
Granted |  | 56,710 | ​ | $ | 120.67
Vested |  | (41,139) | ​ | $ | 115.24
Forfeited |  | — | ​ | $ | —
Exercised | ​ | — | ​ | $ | —
Outstanding at December 31, 2023 |  | 136,113 | ​ | $ | 118.84
​ As of December 31, 2023, total unrecognized stock-based compensation expense related to Restricted Stock was approximately $7.2 million, which is expected to be recognized over the weighted-average vesting period of 1.7 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration